Adeno-associated virus variant capsids and use for inhibiting angiogenesis
Provided herein are variant adeno-associated virus (AAV) capsid proteins having one or more modifications in amino acid sequence relative to a parental AAV capsid protein, which, when present in an AAV virion, confer increased infectivity of one or more types of retinal cells as compared to the infectivity of the retinal cells by an AAV virion comprising the unmodified parental AAV capsid protein. Also provided are recombinant AAV virions and pharmaceutical compositions thereof comprising a variant AAV capsid protein as described herein, methods of making these rAAV capsid proteins and virions, and methods for using these rAAV capsid proteins and virions in research and in clinical practice, for example in, e.g., the delivery of nucleic acid sequences to one or more cells of the retina for the treatment of retinal disorders and diseases.
1. A nucleic acid encoding an inhibitor of VEGF-A, said nucleic acid comprising one or more of:
(i) the nucleotide sequence set forth as SEQ ID NO:65 (aflibercept) or a nucleotide sequence at least 90% identical to the nucleotide sequence set forth as SEQ ID NO:65 and which encodes the amino acid sequence set forth as SEQ ID NO:66; and
(ii) the nucleotide sequence as set forth in nucleotides 79-1377 of SEQ ID NO:65 (aflibercept) or a nucleotide sequence at least 90% identical to the nucleotide sequence set forth in nucleotides 79-1377 of SEQ ID NO:65 and which encodes the amino acid sequence of amino acids 27-458 of SEQ ID NO:66.
2. The nucleic acid according to claim 1 , wherein the nucleotide sequence is at least at least 95% identical to the nucleotide sequence set forth in SEQ ID NO:65 and encodes the amino acid sequence set forth as SEQ ID NO:66.
3. The nucleic acid according to claim 1 , wherein the nucleotide sequence is at least at least 99% identical to the nucleotide sequence set forth in SEQ ID NO:65 and encodes the amino acid sequence set forth as SEQ ID NO:66.
4. An adeno-associated virus (AAV) vector comprising a nucleic acid according to claim 1 , wherein the nucleotide sequence set forth in (i) or (ii) is operably linked to an expression control sequence.
5. The rAAV vector according to claim 4 , wherein the expression control sequence comprises a ubiquitous promoter.
6. The rAAV vector according to claim 5 , wherein the ubiquitous promoter is selected from a CMV, CAG and CBA promoter.
7. The AAV vector according to claim 4 , wherein the AAV vector comprises (a) a nucleic acid comprising the nucleotide sequence set forth in (i) or (ii), said nucleotide sequence operably linked to an expression control sequence and (b) a variant adeno-associated virus (AAV) capsid protein comprising a peptide insertion in the GH-loop of the capsid protein corresponding to the capsid protein of SEQ ID NO: 2, wherein the peptide insertion comprises the amino acid sequence of SEQ ID NO: 14.
8. The rAAV vector according to claim 7 , wherein the peptide insertion is 7 to 10 amino acids in length and comprises SEQ ID NO: 14.
9. The rAAV vector according to claim 8 , wherein the peptide insertion comprises the amino acid sequence of SEQ ID NO:28.
10. The rAAV vector according to claim 7 , wherein the insertion site is between amino acids corresponding to amino acids 587 and 588 of SEQ ID NO:2.
11. The rAAV vector according to claim 7 , wherein the capsid protein further comprises one or more amino acid substitutions.
12. The rAAV vector according to claim 11 , wherein the capsid protein comprises a P34A amino acid substitution in the VP1 capsid corresponding to position 34 of SEQ ID NO: 2.
13. The rAAV vector according to claim 12 , wherein the capsid protein is at least 90% identical to the sequence set forth as SEQ ID NO:42.
14. The rAAV vector according to claim 13 , wherein the capsid protein comprises the amino acid sequence set forth as SEQ ID NO:42.
15. The rAAV vector according to claim 7 , wherein the nucleic acid of (i) or (ii) further comprises a nucleotide sequence encoding an interfering RNA that inhibits angiogenesis.
16. The rAAV vector according to claim 15 , wherein the interfering RNA decreases expression of a pro-angiogenic gene product selected from VEGFa, VEGFb, VEGFc, VEGFd, VEGFR1, VEGFR2, VEGFR3, PGF, PDGF and an angiopoietin.
17. The rAAV vector according to claim 16 , wherein the interfering RNA decreases expression of VEGFc and wherein the capsid protein comprises the amino acid sequence set forth as SEQ ID NO:42.
18. A pharmaceutical composition comprising the nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising the rAAV according to claim 4 and a pharmaceutically acceptable carrier.
20. The pharmaceutical composition according to claim 19 , wherein the rAAV comprises a capsid protein comprising the amino acid sequence set forth as SEQ ID NO:42 or an amino acid sequence at least 95% identical thereto.
21. The pharmaceutical composition according to claim 20 , wherein the capsid protein comprises the amino acid sequence of SEQ ID NO:42.
22. The pharmaceutical composition according to claim 21 , wherein the nucleic acid of (i) or (ii) further comprises a nucleotide sequence encoding an interfering RNA that inhibits VEGFc.
23. A method for delivering a VEGF inhibitor to a retinal cell, choroidal cell, lenticular cell, ciliary cell, iris cell, optic nerve cell and/or corneal cell in a subject, the method comprising administering to the subject the pharmaceutical composition according to claim 18 .
24. A method for delivering a VEGF inhibitor to a retinal cell, choroidal cell, lenticular cell, ciliary cell, iris cell, optic nerve cell and/or corneal cell in a subject, the method comprising administering to the subject the pharmaceutical composition according to claim 19 .
25. A method to treat a VEGF-associated ocular disease selected from wet age-related macular degeneration; macular edema following retinal vein occlusion; retinal neovascularization resulting from retinal vein occlusion; diabetic macular edema, diabetic retinopathy; myopic macular degeneration; branch retinal vein occlusion, hemi-retinal vein occlusion, and central retinal vein occlusion; retinopathy of prematurity; idiopathic choroidal neovascularization; myopia macular degeneration and secondary retinal and choroidal neovascularization; retinal telangiectasia; neovascular glaucoma; vitreous hemorrhage; retinal and choroidal neovascularization secondary to retinal diseases, including but not limited to uvetis, trauma, retinal degenerative disorders, genetic retinal and/or choroidal disease, tumors of the eye, corneal and iris neovascularization in a subject in need of such treatment comprising administering to the subject the pharmaceutical composition according to claim 18 .
26. A method to treat a VEGF-associated ocular disease selected from wet age-related macular degeneration; macular edema following retinal vein occlusion; retinal neovascularization resulting from retinal vein occlusion; diabetic macular edema, diabetic retinopathy; myopic macular degeneration; branch retinal vein occlusion, hemi-retinal vein occlusion, and central retinal vein occlusion; retinopathy of prematurity; idiopathic choroidal neovascularization; myopia macular degeneration and secondary retinal and choroidal neovascularization; retinal telangiectasia; neovascular glaucoma; vitreous hemorrhage; retinal and choroidal neovascularization secondary to retinal diseases, including but not limited to uvetis, trauma, retinal degenerative disorders, genetic retinal and/or choroidal disease, tumors of the eye, corneal and iris neovascularization in a subject in need of such treatment comprising administering to the subject the pharmaceutical composition according to claim 19 .
27. The method according to claim 26 , wherein the rAAV comprises (i) a capsid protein comprising the amino acid sequence set forth as SEQ ID NO:42 or an amino acid sequence at least 95% identical thereto.
28. The method according to claim 27 , wherein the nucleic acid of (i) or (ii) further comprises a nucleotide sequence encoding an interfering RNA that inhibits VEGFc.
29. The method of claim 28 , wherein the VEGF-associated ocular disease is selected from wet age-related macular degeneration; diabetic macular edema; macular edema following retinal vein occlusion; diabetic retinopathy; and myopic choroidal neovascularization.
30. The method of claim 25 , wherein the pharmaceutical composition is administered intraocularly to the subject.
31. The method according to claim 30 , wherein the pharmaceutical composition is administered to the subject by intravitreal, subretinal and/or suprachoroidal injection.
32. The method of claim 27 , wherein the pharmaceutical composition is administered intraocularly to the subject.
33. The method according to claim 32 , wherein the pharmaceutical composition is administered to the subject by intravitreal, subretinal and/or suprachoroidal injection.